Palatin Technologies (PTN) Profit After Tax (2010 - 2026)
Palatin Technologies' (PTN) quarterly Profit After Tax came in at -$1.4 million in Q1 2026, up 70.22% YoY from -$841859.1 in Q1 2025, and up 80.27% on a QoQ basis from -$7.3 million in Q4 2025.
Palatin Technologies (PTN) Profit After Tax (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Profit After Tax data on file, last reported at -$1.4 million in Q1 2026.
- Quarterly Profit After Tax rose 70.22% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.2 million (up 73.21% YoY) and the FY2025 annual result came in at -$17.3 million, up 41.8% from the prior year.
- Profit After Tax improved to -$1.4 million in Q1 2026, from -$7.3 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $4.7 million in Q3 2025 to a low of -$12.8 million in Q2 2022.
- A 5-year average of -$5.6 million and a median of -$7.6 million in 2022 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax sank 389.72% — and 2025, when it jumped 159.79%.
- Tracing PTN's Profit After Tax over 5 years: stood at $2.7 million in 2022, then slumped by 389.72% to -$7.8 million in 2023, then jumped by 68.86% to -$2.4 million in 2024, then slumped by 197.4% to -$7.3 million in 2025, then soared by 80.27% to -$1.4 million in 2026.
- The last three Profit After Tax figures came in at -$1.4 million (Q1 2026), -$7.3 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | -1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.43 Mn |
| Dec 31, 2025 | -7.26 Mn |
| Sep 30, 2025 | 4.68 Mn |
| Jun 30, 2025 | -2.23 Mn |
| Mar 31, 2025 | -4.81 Mn |
| Dec 31, 2024 | -2.44 Mn |
| Sep 30, 2024 | -7.82 Mn |
| Jun 30, 2024 | -8.25 Mn |
| Mar 31, 2024 | -8.44 Mn |
| Dec 31, 2023 | -7.84 Mn |
| Sep 30, 2023 | -5.21 Mn |
| Jun 30, 2023 | -9.82 Mn |
| Mar 31, 2023 | -8.67 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Sep 30, 2022 | -8.26 Mn |
| Jun 30, 2022 | -12.77 Mn |
| Mar 31, 2022 | -7.63 Mn |
| Dec 31, 2021 | -8.69 Mn |
| Sep 30, 2021 | -7.11 Mn |
| Jun 30, 2021 | -13.93 Mn |